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ABSTRACT 
Despite recent advances, allografting remains the only potential cure for myeloma. From July 
1999 to June 2005, 100 newly diagnosed patients younger than 65 years were enrolled in a 
prospective multi-center study. First-line treatment included vincristin, adriamycin and 
dexamethasone (VAD)-based induction chemotherapy, a cytoreductive autograft (melphalan 200 
mg/m2) followed by a single dose of non-myeloablative total body irradiation and allografting from 
an HLA-identical sibling. Primary endpoints were overall (OS) and event-free (EFS) survivals from 
diagnosis. After a median follow up of 5 years, OS was not reached and EFS was 37 months. 
Incidences of acute and chronic graft-vs.-host disease (GHVD) were 38% and 50%, respectively. 
Complete remission (CR) was achieved in 53% of patients. Profound cytoreduction (CR or very 
good partial remission) prior to allografting was associated with achievement of post-transplant CR 
(HR 2.20, p=0.03) and longer EFS (HR 0.33, p<0.01). Conversely, development of chronic GVHD 
was not correlated with CR or response duration. This tandem transplant approach allows prolonged 
survival and long-term disease control in patients with reduced tumor burden at the time of 
allografting. We are currently investigating the role of “new drugs” in intensifying pre-transplant 
cytoreduction and post-transplant graft-vs.-myeloma effects to further improve clinical outcomes. 
(ClinicalTrial.gov, NCT-00702247) 
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INTRODUCTION 
Despite remarkable recent advances in its treatment, multiple myeloma remains incurable.
1
 
Allografting is still regarded as the only potential cure on account of its well-documented graft-vs.-
myeloma effect observed in a subset of patients.
2-5
 However, its use remains controversial 
especially in newly diagnosed patients.  
In the late ‘90s, the introduction of reduced intensity / non-myeloablative conditionings 
greatly renewed the interest in allografting in particular for diseases such as myeloma where the 
transplant-related mortality (TRM) with conventional transplant regimens had been unacceptably 
high.
5-7
 Combining the cytoreductive effect of a high-dose melphalan-based autograft with the 
graft-vs.-myeloma effects of a non-myeloablative allograft reduced TRM even in elderly, medically 
unfit myeloma patients.
8,9
  
Our recent comparison between autografting and non-myeloablative allografting showed that 
the latter resulted in longer overall and event-free survivals in newly diagnosed patients younger 
than 65 years.
10
 Preliminary reports from other groups have confirmed our findings.
11,12
 Here, we 
report on an extended experience consisting of 100 newly diagnosed myeloma patients enrolled in a 
prospective clinical trial (ClinicalTrial.gov, NCT-00702247) and treated with non-myeloablative 
allografts as part of their first-line treatment at fifteen Italian Bone Marrow Transplantation Units of 
the Gruppo Italiano Trapianti di Midollo Osseo (GITMO). 
 
METHODS 
Patients and donors From July 1999 to June 2005, 100 newly diagnosed myeloma patients 
younger than 65 years were enrolled in a prospective multi-center trial. Informed consent was 
obtained upon enrolment. The protocol was approved by the Institutional Review Boards of the 
participating Centers according to the Declaration of Helsinki.  
Inclusion criteria included: diagnosis of untreated Durie & Salmon stage IIA-IIIB multiple 
myeloma or stage I progressed to require therapy; age < 65 years; Karnofsky performance status 
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>60%; presence of an HLA-identical sibling donor eligible for peripheral blood stem cell (PBSC) 
donation. Exclusion criteria included: prior treatment for myeloma; abnormal cardiac function and 
chronic respiratory disease defined as systolic ejection fraction < 35% and carbon monoxide 
diffusing capacity < 40% of predicted or need of continuous supplemental oxygen, respectively; 
serum bilirubins > twice normal, and ALAT and/or ASAT > four times normal; poorly controlled 
hypertension; pregnancy, seropositivity for HIV. Patients with active non-hematologic 
malignancies, except non-melanoma skin cancers, or who were less than 5 years from the 
achievement of complete remission with a >20% risk of disease recurrence were also excluded. 
Sibling donors < 75 years of age were serologically matched for HLA-A , B and C antigens, 
and by high resolution typing for HLA-DRB1 and DQB1 alleles. Donors gave consent to 
granulocyte-colony stimulating factor (G-CSF) administration and to leukapheresis for PBSC 
collections. Pregnant women, identical twins, HIV-positive individuals and potential donors with 
known allergy to G-CSF were excluded from donation.  
 Induction therapy, PBSC mobilization and autografting Initial treatment plan included 
induction chemotherapy, mainly consisting of 2-3 courses of vincristine-adriamycin-dexamethasone 
(VAD)-based regimens, followed by PBSC mobilisation and harvest (target of at least 2 x 10
6
 
CD34 cells/kg) after 1 or 2 cycles of cyclophosphamide, 3-4 g/m
2
, with or without paclitaxel, 250 
mg/m
2
, and G-CSF, 10 g/kg given i.v. or subcutaneously. After at least one month from PBSC 
collection, autografting consisted of melphalan, 200 mg/m
2
, on day –2, and cryopreserved PBSC 
infusion on day 0. Patients received G-CSF, 5 g/kg, from days 1 or 3 until neutrophil counts 
>1000/ l were achieved.  
Donor mobilisation HLA-identical sibling donors, mean age 54 (range 32-69) years, were 
mobilised with G-CSF, 16 g/kg/day (day –4 to 0), with aphereses on days –1 and 0. PBSC 
harvested on day –1 were stored overnight at 4ºC and freshly infused with the day 0 collection.  The 
entire collections were infused and a minimum target of 5 x 10
6
 CD34-positive cells/kg of recipient 
body weight was recommended. No upper limit was defined.  
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Non-myeloablative allografting Upon recovery from autografting, defined as resolved 
mucositis, no evidence of cytomegalovirus (CMV) reactivation or disease, and no need for 
intravenous medications, planned range of 2-4 months, patients were conditioned for allografting 
with a single dose of non-myeloablative 200 cGy total body irradiation (TBI) on day 0. Postgrafting 
immunosuppression consisted of mycophenolate mofetil, 15 mg/kg orally BID from the evening of 
day 0 until day 27, and cyclosporine, 6.25 mg/kg orally BID from day -3 or 1.5 mg/kg iv BID from 
day -1 through day 80 and then tapered.
9,10
 No maintenance/consolidation therapy was allowed by 
protocol after non-myeloablative allografting.  
Analyses of chimerism Chimerism analyses of peripheral blood T cells, granulocytes and 
unfractionated marrow were carried out at days 28, 56, 180, 360 after allografting and every six 
months thereafter or as clinically indicated with fluorescence in situ hybridization (FISH) in sex-
mismatched pairs or polymerase chain reaction (PCR)-based analyses of polymorphic microsatellite 
regions in sex-matched pairs as previously described.
9,10
  
Chromosomal abnormalities 13q deletion (del13) was analysed by interphase FISH 
techniques on freshly purified bone marrow plasma cells as previously described.
13
 
Supportive care and GVHD grading Following allografting, all patients received standard 
prophylaxis against bacterial and fungal infections; herpes simplex and varicella-zoster virus 
reactivation; and Pneumocystis carinii. CMV reactivation was monitored through levels of CMV 
antigenemia and/or serum CMV DNA levels and treated with ganciclovir or foscarnet as clinically 
indicated. Standard criteria were used for diagnosis and grading of acute and chronic GVHD.
14,15
  
Salvage therapy Standard chemotherapy and/or thalidomide- or bortezomib-containing 
regimens, as per Institutional guidelines of the participating Centers, with/without donor 
lymphocytes infusions (DLI) were allowed to treat progression or relapse post-transplant. DLI were 
administered in the absence of GVHD clinical manifestation and after a rapid taper and 
discontinuation of the immunosuppression. 
 7 
  Disease response Response was evaluated prior to each treatment, monthly for the first six 
months following allografting and at least every three months thereafter or as clinically indicated. 
Response criteria were defined according to the International Uniform Response Criteria for 
multiple myeloma.
16
 Complete remission (CR) required absence of serum monoclonal 
immunoglobulins and/or Bence-Jones proteinuria by electrophoresis and immunofixation, less than 
5% plasma cell infiltration in bone marrow aspirates, absence of soft tissue lesions and no increase 
in size or number of osteolytic lesions. Very good partial remission (VGPR) was defined as 
detection of serum monoclonal immunoglobulins and/or Bence-Jones proteinuria by 
immunofixation but not by electrophoresis or at least 90% reduction in Bence-Jones proteinuria 
with excretion lower than 100 mg /24-hour, and no increase in size or number of osteolytic lesions. 
Partial remission (PR) was defined as >75% reduction in the levels of serum monoclonal 
immunoglobulin, at least 90% reduction in 24-hour urinary light chain excretion, and no increase in 
size or number of lytic bone lesions. Patients with less than a PR after induction chemotherapy or 
autografting were considered refractory, whereas the disease was considered stable if no response, 
meeting the criteria of CR, VGPR or PR, was observed after allografting. Response criteria had to 
be met on at least two consecutive occasions at least six weeks apart. Progressive disease (PD) was 
considered an increase in serum monoclonal proteins or urine light chains of a least 25% in patients 
with refractory or stable disease, whereas relapse was considered as the reappearance of bone 
marrow infiltration, serum monoclonal immunoglobulins or urine light chains or new bone lesions 
in patients in previous CR, or a 25% increase in any disease marker for patients in prior PR.  
Statistical analysis Primary endpoints of the study were overall (OS) and event-free survivals 
(EFS) from diagnosis according to the intention-to-treat principle and in patients who completed the 
program. Secondary endpoints included transplant-related toxicity and TRM and incidence of acute 
and chronic GVHD. OS and EFS were calculated according to the Kaplan-Meier technique from the 
date of diagnosis until death from any cause and from the date of diagnosis until the date of first 
relapse or progression or of death from any cause, respectively.
17
 Deaths not related to myeloma or 
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to non-hematological malignancies were classified as deaths from transplant-related toxicity. 
Moreover, an estimation of the probability that a patient was alive in the original remission or in a 
subsequent remission after salvage treatment was carried out by the “Current Progression Free 
Survival” (CPFS) method as described by Klein et al.18 Estimates of the incidence of acute and 
chronic GVHD, TRM and disease-related mortality were calculated with the cumulative incidence 
method described by Gooley et al, in which risks of death in CR and of relapse were considered as 
competing risks.
19
 The individual effect of patient characteristics on time from allografting to five 
different events (relapse/progression, death, CR after transplant, chronic extensive GVHD and acute 
grade II-IV GVHD) were evaluated using Cox's proportional-hazards regression models with the 
Wei-Lin-Weissfeld estimators.
20-23
 Proportional hazard assumptions were checked with the 
Grambsh and Therneau test.
24
 Predictors were chosen for each outcome in the light of potential 
clinical impact and sample size as follows: prognostic role of age, isotype of myeloma protein, 
International Staging System (ISS) score, disease in remission, defined as VGPR or CR, at the time 
of allografting and comorbidity index ≥ 3 for both OS and EFS; chronic GVHD, as time-dependent 
covariate, age, isotype of myeloma protein, ISS, disease in remission at the time of allografting for 
both the achievement of CR and the risk of relapse/progression post-allografting; effects of CD34-
pos cells and CD3-pos T cells infused, age and donor gender for the risk of developing acute and 
chronic GVHD.
25-26
 Results are presented as hazard ratios (HR) with corresponding 95% 
confidence intervals (95% CI) and p-values. SAS 8.2 statistical software (SAS Institute, Cary, NC) 
and R.2.1.0 software, package cmprsk were used. 
 
RESULTS 
 Patients Patient characteristics are shown in Table 1. Overall, 100 patients with at least one 
HLA-identical sibling were enrolled at fifteen Italian Bone Marrow Transplantation Units. Ninety-
six/100 (96%) completed the protocol whereas 4 did not because of consent withdrawal (no=2); 
infectious complications after the autograft (no=1); ineligible donor at pre-transplant work-up 
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(no=1). Fifty-two, also described in an earlier report, have been included in this series after 
updating their follow-up.
10
   
Engraftment and Response Ninety-six allografts were carried out at a median of 90 (range 
44-396) days after the autograft. One patient underwent the allograft 13 months after the autograft 
because of viral encephalitis. The median numbers of CD34+ cells and CD3+ T cells infused were 
7.5 x 10
6
/Kg (range, 2.6-26.4 x10
6
) and 3.2 x 10
7
/Kg (range, 0.7-18.9 x10
7
) recipient body weight, 
respectively. All patients readily achieved engraftment with median percentages of donor cells at 1 
month post transplant of 97%, 97%, and 97% among blood T-cells, granulocytes and unfractionated 
bone marrow respectively.  
 Forty-eight/100 patients had chemo-sensitive disease (2 CR, 6 VGPR, and 40 PR) at the 
time of autografting, while, among the 96 patients who completed the program, 6 (6%) were in CR, 
29 in VGPR (30%) and 38 (40%) in PR at the time of allografting. Overall, after the allograft, 51 
(53%) patients achieved CR at a median of 4 (range 1-45) months, 15 (16%) VGPR and 21 PR 
(22%), giving an overall response of 91%. With a median follow-up of 5 (range 2.3-8.4+) years 
from diagnosis and 4.3 (1.8-7.4+) from allografting, 14/51 (27%), 10/15 (67%) and 12/21 (57%) 
patients had relapsed from CR, VGPR and PR respectively, giving an overall relapse rate of 41% 
(36/87). Overall response and relapse rates for the entire cohort of patients were 88% (88/100) and 
44% (39/88) respectively. Disease-related mortality was 5.2% at 2 years (95% CI: 0.8-9.6%); 20.5 
at 5 years (95% CI: 11.7-29.3%) (Figure 1-C).   
Salvage Therapy Thirty-six patients were treated for disease relapse and 6 for progression of 
stable disease. First-line salvage therapy consisted of bortezomib- or thalidomide-containing 
regimens in 12 and 16 patients, respectively, and standard chemotherapy and/or radiotherapy in 8. 
Moreover, 9 of these patients received DLI as consolidation therapy. Five patients received DLI 
alone. In one patient, the immunosuppression was tapered and eventually discontinued without 
further therapy. Overall, 6/42 (14%) patients obtained a CR and 13/42 (31%) a PR. Five patients 
experienced a second relapse.  
Formattato
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Only 4 patients received DLI for post-transplant stable disease. Overall, among the 18 treated 
with DLI, only 1 (7%) patient reached CR and 3 (17%) others PR. 
Transplant-related Toxicity Thirty-six patients developed grade II-IV acute GVHD at a 
median of 41 (range 20-115) days. This was grade IV in 3 patients. Cumulative incidence of grade 
II-IV and grade IV GVHD was 38% and 3%, respectively (Figure 1-A). Forty-seven (50%) of 94 
patients with a follow-up of at least 120 days developed extensive chronic GVHD. Overall, 53/85 
patients, 27/73 and 10/36 remained on immunosuppression at 1, 2 and 4 years post-allografting 
respectively. Six/53 patients who developed acute GVHD had a flare after initial therapy that 
required an immunosuppression taper longer than one year. Most patients had a Karnofsky 
performance status of 90-100% despite immunosuppression. One patient in CR with severe 
bronchiolitis obliterans successfully underwent lung transplantation. Twenty-nine (30%) patients 
have died: 15 (16%) from disease progression, 11 (11%) from transplant-related toxicity and 3 from 
another malignancy. TRM was due to progressive encephalopathy (n=1), complications associated 
with acute or chronic GVHD (n=8), and HUS-TTP syndrome (n=2). Overall transplant-related 
mortality was 11.4% (95% CI: 4.8-17.2%) (Figure 1-B). By multivariable analysis, an increasing 
number of CD34+ cells infused, but not CD3+ T cells, was associated with a significant risk of 
developing acute GVHD, but not chronic GVHD (HR 1.12, CI 95% 1.04-1.21, p<0.01 and HR 
1.03, CI 95% 0.94-1.13, p=0.55) (Table 2). Furthermore, the development of chronic GVHD was 
not significantly associated with either the subsequent achievement of CR or disease 
relapse/progression (HR 0.80, CI 95% 0.43-1.47, p=0.47 and HR 0.85, CI 95% 0.51-1.42, p=0.54) 
(Table 2).  
Outcome By the intention to treat principle, after a median follow up of 5 (range 0.7-8.4+) 
years from diagnosis, median OS was not reached and median EFS was 2.9 (range 2.4-4.3) years 
(Figure 2-A, 2-B). Among the 96 patients who completed the program, after a median follow up of 
5 (range 2.3-8.4+) years from diagnosis, median OS was not reached whereas median EFS was 3.1 
(range 2.6-4.5) years (Figure 2-C, 2-D). No differences in both the updated OS and EFS between 
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the previously reported cohort of 52 patients
10
 and the newly described 44 were observed (HR 0.58, 
CI 95% 0.28-1.2, p=0.14 and HR 0.93, CI 95% 0.55-1.56, p=0.78, respectively). Furthermore, the 
probability of a patient being alive in first remission or in a subsequent remission due to salvage 
therapy is illustrated in Figure 3. 
Multivariable analyses for OS and EFS are reported in Table 3. Irrespective of myeloma 
isotype, ISS, comorbidity index ≥ 3, disease in remission was significantly associated with longer 
OS and EFS (HR 0.20, CI 95% 0.06-0.67, p=0.01 and HR 0.33, CI 95% 0.17-0.65, p<0.01). Age, as 
a continuous variable, was also significantly associated with both OS and EFS (HR 1.06, CI 95% 
1.00-1.14, p=0.05 and HR 1.07, CI 95% 1.02-1.12, p<0.01, respectively). Chromosome 13 
abnormalities [del(13)] were studied in 39/96 (41%) patients: 13/39 (33%) showed del(13) whereas 
26/39 (67%) did not. There was no significant difference in median OS between the two cohorts of 
patients (not reached vs. 4.3 years, p=0.18) whereas EFS was better in patient without del(13) (4.3 
vs. 2.2 years, p=0.01) (Figure 4-A, 4-B). 
 
DISCUSSION 
 Progress in myeloma treatment has been impressive in the past ten years with the 
introduction of high-dose melphalan followed by autologous transplantation and, recently, through 
the identification of new agents with molecular targets such as thalidomide, lenalidomide and 
bortezomib.
27-32
 OS has been significantly prolonged especially in good risk patients, whereas 
eradication of the disease seems unlikely. Conversely, in the light of a well-documented graft-vs.-
myeloma effect, allografting may be curative in a subset of patients.
5,33,34
 However, its role has 
never been thoroughly investigated. First, the high transplant-related toxicity associated with 
myeloablative conditionings has severely limited its application; second, the retrospective nature of 
several studies with strong patient selection bias and the lack of large prospective controlled trials 
have not allowed definitive conclusions.
7
 One of the strengths of our study is the rigid enrolment at 
diagnosis of untreated myeloma patients who underwent the same VAD-based induction treatment 
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before the autologous cytoreductive transplant. This strategy meant that they were all treated 
uniformly and any statistical bias was greatly reduced. By contrast, prospective studies which 
include allografting as part of the up-front treatment regardless of the induction therapy inevitably 
result in bias that may highly affect the clinical outcomes.   
 
In the present study, median OS was not reached after a follow-up of 5 years. Before the era 
of “new drugs”, after a median follow-up of 75 months, Attal et al. reported median OS of 48 and 
58 months after one and two autologous transplants respectively.
28
 Barlogie et al.
35
 reported that 
17% of the patients enrolled in the Total Therapy 1 trial  were alive at 15 years, 7% event free, after 
a median follow-up of 12 years. 
29 
More recently, with a follow-up of 7 years, the thalidomide arm 
of Total Therapy 2 has appeared to further improve clinical outcomes.
 35
  
 
Overall, 53% (51/96) of patients reached CR, 73% (37/51) of whom are in continuous CR, 
including molecular remissions (Ladetto M., personal communication), prelude to a cure, with a 
follow-up extending to 8 years. Thus, the depth of response was crucial for prolonged response in 
our study (Table 3).
36
 Given the high rate of CR obtained without the use of so-called “new drugs”, 
it is imperative to thoroughly explore their role in the setting of allografting. Graft-vs.-myeloma 
effects and “new drugs” with molecular targets, in fact, are by no means mutually exclusive. 
Bortezomib and thalidomide have already been shown to re-induce remissions in patients who 
relapsed following allografting.
37-34
 Anti-myeloma activity has also been shown at relapse in the 
series of patients reported in this study (Figure 3). We are currently investigating the role of 
lenalidomide in reducing the tumor burden before and enhancing graft-vs-myeloma effect after 
transplant. Maintenance therapy may lead to a significant increase in response rates and prolonged 
response duration. Furthermore, this strategy may also overcome the higher risk of relapse in 
patients with poor prognostic factors. 
40
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Overall, non-relapse mortality was 11%. GVHD and its complications accounted for most 
TRM. Its incidence, however, may be further reduced as progress is made in the understanding of 
its pathogenesis.
41
 Chronic GVHD has often been associated with longer response duration and 
better OS.
42
 In our study, however, its development did not correlate with either subsequent 
achievement of CR or response duration (Table 2). In a subset of patients, therefore, a graft-vs.-
myeloma effect may be distinct from detrimental chronic GVHD or associated with subclinical 
graft-vs.-host reactions. The potential biological effects of the number of donor CD34-pos cells 
infused have been debated in several studies.
43,44
 Interestingly, we noted that an increasing number 
of CD34-pos cells infused, but not CD3-pos T cells, was significantly correlated with a higher risk 
of developing acute GVHD (Table 2). An upper limit of CD34-pos cells infused was not included in 
our trial. Evaluation of their number in a larger series of patients may help to set a range that allows 
consistent donor engraftment while reducing the risk of acute GVHD.  
 
It is widely assumed that chromosomal abnormalities are important prognostic factors for 
both OS and EFS.
45
 Garban et al. reported OS and EFS of 35 and 31.7 months respectively, after a 
median follow-up of 2 years, in high risk newly diagnosed myeloma patients, with either elevated 
β-2-microglobulin levels or presence of del(13), who received reduced-intensity allografts.46 
Perhaps because the conditioning with high-dose anti-thymocyte globulin may have attenuated 
graft-vs.-myeloma effects, a survival benefit with allografting as compared to melphalan-based 
autografting was not observed.
47
 In another comparison, the advantage of having an HLA identical 
sibling, therefore the chance of undergoing an allograft, as compared to not having an HLA-
identical sibling was not offset by the presence of del(13).
10
 This finding, however, did not imply 
that in patients given allografts, del(13) might not have had a prognostic role. In the present series, 
del(13) appeared to significantly affect EFS (4.3 vs. 2.2 years, p=0.01), but not OS (not reached vs. 
4.3 years, p=0.18). The data reported in all these studies should, however, be evaluated with larger 
and more comprehensive analyses that include a complete spectrum of the chromosomal 
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abnormalities associated with myeloma rather than a single abnormality. Recent reports clearly 
showed that del(13) alone did not affect OS after transplant unless it was associated with other 
abnormalities such as del(17) or t(4;14).
47
 
  
Whether an allograft should be offered as part of first-line treatment plan or as salvage 
therapy for refractory or relapsed patients is a matter of debate.
48
 Though allografting with reduced 
intensity/non-myeloablative conditionings has evolved into a less toxic procedure, new methods to 
further reduce toxicity while maintaining graft-vs.-myeloma effects are being investigated. In our 
experience, the use of low-dose TBI conditioning regimens up-front proved significantly more 
effective in terms of graft-vs.-myeloma effects than waiting with transplant until relapse.
49
 Poor 
response to post-transplant donor lymphocyte infusions at relapse, without prior cytoreduction, was 
also observed. These might be due to an antigen expression profile of potential targets for 
allogeneic cytotoxic T cells that progressively changed. For instance, Siegel et al. identified HLA-
A*0201-presented T cell epitopes derived from the oncofetal antigen-immature laminin receptor 
protein in hematological malignancies including myeloma.
50
 Expression of these antigens on 
myeloma cell was lost over time. Rosinol et al recently reported on the PETHEMA study.
 12
 
Patients who did not achieve at least near-CR after a first autograft were randomized to receive 
either a second autograft or an allograft after a reduced-intensity-conditioning in the light of the 
presence/absence of an HLA-identical sibling donor. There was a significantly higher incidence of 
CR and a longer progression-free survival in patients treated with an allograft. However, there was 
also a higher TRM and no statistical difference in EFS and OS. The Authors concluded that, 
although the progression-free survival plateau was encouraging, the procedure should be 
investigated in prospective clinical trials. Though different in design, the findings of the PETHEMA 
study are not conflicting with our trial. In particular, we clearly observed that disease response at 
the time of the allograft was significantly associated with post-transplant EFS and OS (Tables 2 and 
3). 
 15 
 
In summary, our findings suggested that allografting was effective in the treatment of newly 
diagnosed myeloma patients. The combination of graft-vs.-myeloma effects with “new drugs” 
should be clinically evaluated in well-designed phase III clinical trials where control groups should 
include patients treated with new agents with potent anti-myeloma activity with/without 
autografting. Moreover, stratification of patients by prognostic factors, especially chromosomal 
abnormalities, is imperative to determine those who may most benefit from a “tandem transplant 
approach”. 
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TABLE 1 
 
Patient characteristics 
 
Characteristic 
Patients enrolled (n=100) 
Number (%) 
Patients who completed 
program (n=96) 
Number (%) 
Male 52 (52) 52 (54) 
Mean age, years (range) 54 (30-65) 54 (30-65) 
Durie&Salmon Stage II 29 (29) 26 (27) 
Durie&Salmon Stage III 67 (67) 66 (69) 
International Staging System 2 22/92 (24) 22/88 (25) 
International Staging System 3 14/92 (15) 12/88 (14) 
Ig-G myeloma 57 (57) 56 (58) 
Ig-A myeloma 18 (18) 18 (19) 
Ig-D myeloma 1 (1) 0 
Bence Jones myeloma 18 (18) 17 (18) 
Non-secretory myeloma 6 (6) 5 (5) 
-2-microglobulin > 3.5 mg/dl 33/95 (35) 31/91 (34) 
Albumin <3.5 g/dl 21/95 (22) 21/92 (23) 
Creatinine >2 mg/dl 11 (11) 11 (11) 
LDH above normal level 17/91 (19) 16/88 (18) 
Presence of Ch 13 deletion 14/43 (33) 13/39 (33) 
HCT-Specific Comorbidity Index ≥ 3 11 (11) 10 (10) 
Abbreviations: LDH lactate dehydrogenase; HCT Hematopoietic Cell Transplantation 
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TABLE 2 
  
Cox models for achievement of complete remission, for progression/relapse and for 
development of acute and chronic GVHD 
 
 Multivariable Analyses 
Variable Achievement of CR 
 
Progression/relapse 
 HR (95% CI) P-value   HR (95% CI) P-value 
Development of chronic GVHD° 0.80 (0.43-1.47) 0.47  0.85 (0.51-1.42) 0.54 
Age* 0.96 (0.92-1.00) 0.05  1.08 (1.03-1.13) <0.01 
Ig-G Myeloma 0.77 (0.45-1.30) 0.33  0.61 (0.35-1.06) 0.08 
International Staging System 3 0.66 (0.22-1.98) 0.46  1.39 (0.69-2.79) 0.35 
Disease in remission
§
 at allografting 2.20 (1.18-4.08) 0.03  0.30 (0.15-0.62) <0.01 
 
Development of          
Acute GVHD 
 
Development of      
Chronic GVHD 
 HR (95% CI) P-value   HR (95% CI) P-value  
CD3+ cells/Kg recipient weight* 0.98 (0.81-1.18) 0.85  1.05 (0.97-1.13) 0.23 
CD34+ cells/Kg recipient weight* 1.12 (1.04-1.21) <0.01  1.03 (0.94-1.13) 0.55 
Age* 1.03 (0.98-1.09) 0.25  1.05 (1.01-1.10) 0.02 
Female donor 2.11 (1.00-4.45) 0.05  1.06 (0.54-2.08) 0.86 
°Time-dependent variable *Continuous variable §Defined as VGPR and CR 
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TABLE 3 
 
Cox models for overall and event free survivals 
 
 Multivariable Analyses 
Variable Overall survival 
 
Event free survival 
 HR (95% CI) P-value   HR (95% CI) P-value  
Age* 1.06 (1.00-1.14) 0.05  1.07 (1.02-1.12) <0.01 
Ig-G Myeloma 0.60 (0.26-1.34) 0.21  0.52 (0.28-0.96) 0.03 
International Staging System 3 1.91 (0.74-4.90) 0.18  1.53 (0.73-3.20) 0.26 
Disease in remission§ at allografting 0.20 (0.06-0.67) 0.01  0.33 (0.17-0.65) <0.01 
HCT-Specific comorbidity Index ≥ 3 0.96 (0.27-3.36) 0.95  0.87 (0.33-2.28) 0.78 
*Continuous variable §Defined as VGPR and CR 
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FIGURE LEGENDS 
 
 
Figure 1 Cumulative incidence estimates of graft-vs-host disease (GVHD) and mortality. 
A. Acute GVHD: grade II-IV GVHD 38% (solid line);  grade IV 3% (dotted line) 
B. Transplant related mortality: 11%  
C. Disease related mortality: 5.2% at 2 years; 20.5% at 5 years  
 
Figure 2 Kaplan Meier estimates of overall and event free survivals after a follow up of 5 years: 
overall (A) and event free survivals (B) by intention to treat principle, overall (C) and event free 
survivals (D) among patients who completed program  
 
Figure 3 
Standard overall survival (gray solid line) by Kaplan-Meier, “current progression free survival” 
(dotted line) as described by Klein et al. (see text, Methods section) which includes responses to 
salvage therapies, and standard event free survival (black solid line) by Kaplan-Meier  
 
Figure 4 
A. Overall survival between patients without del13q (solid line; median not reached) and patients 
with del13q (dotted line; median 4.3 years) 
B. Event free survival between patients without del13q (solid line; median 4.3 years) and patients 
with del13q (dotted line; median 2.2 years), P=0.01 
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